Beta Bionics announced upcoming presentations at investor conferences, focusing on advancements in diabetes management solutions.
Quiver AI Summary
Beta Bionics, Inc., a leader in diabetes management solutions, announced that its management will present at two investor conferences: the Wolfe Research 7th Annual Healthcare Conference on November 18, 2025, and the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025. Both presentations will be available via live webcast, with links provided on the company's website under the Investors section, and archived for future viewing. Beta Bionics specializes in developing innovative medical devices, including the iLet Bionic Pancreas, which autonomously adjusts insulin dosing to enhance treatment for individuals with diabetes.
Potential Positives
- Management will present at two significant investor conferences, enhancing visibility and engagement with potential investors.
- The presentations will be webcast live, allowing a wider audience to access information about the company's advancements and strategies.
- The iLet Bionic Pancreas is highlighted as the first FDA-cleared autonomous insulin delivery device, underscoring the company's innovative leadership in diabetes management solutions.
- The focus on improving health outcomes for insulin-requiring individuals positions Beta Bionics favorably within a growing healthcare market.
Potential Negatives
- None
FAQ
What is Beta Bionics presenting at the investor conferences?
Beta Bionics will present advanced diabetes management solutions at two upcoming investor conferences.
When is the Wolfe Research Healthcare Conference?
The Wolfe Research 7th Annual Healthcare Conference is on Tuesday, November 18, 2025, at 2:00 PM ET.
Where can I watch the presentations online?
The presentations will be webcast live and can be found in the "Investors—Events & Presentations" section on their website.
What technology does Beta Bionics focus on for diabetes management?
Beta Bionics develops innovative solutions including the iLet Bionic Pancreas, which utilizes advanced adaptive closed-loop algorithms.
How can I contact Beta Bionics for investor relations?
You can contact Blake Beber, Head of Investor Relations, at [email protected].
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$BBNX Insider Trading Activity
$BBNX insiders have traded $BBNX stock on the open market 31 times in the past 6 months. Of those trades, 0 have been purchases and 31 have been sales.
Here’s a breakdown of recent trading of $BBNX stock by insiders over the last 6 months:
- STEPHEN FEIDER (Chief Financial Officer) has made 0 purchases and 12 sales selling 42,959 shares for an estimated $855,749.
- MARK HOPMAN (Chief Commercial Officer) has made 0 purchases and 7 sales selling 36,103 shares for an estimated $670,738.
- SEAN SAINT (President & CEO) has made 0 purchases and 4 sales selling 6,798 shares for an estimated $124,887.
- MIKE MENSINGER (Chief Product Officer) has made 0 purchases and 4 sales selling 2,204 shares for an estimated $40,489.
- STEVEN JON RUSSELL (Chief Medical Officer) has made 0 purchases and 4 sales selling 2,054 shares for an estimated $37,734.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$BBNX Hedge Fund Activity
We have seen 6 institutional investors add shares of $BBNX stock to their portfolio, and 3 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BANK OF NEW YORK MELLON CORP added 62,765 shares (+229.5%) to their portfolio in Q3 2025, for an estimated $1,247,140
- JENNISON ASSOCIATES LLC removed 59,185 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $1,176,005
- RAKUTEN INVESTMENT MANAGEMENT, INC. added 35,297 shares (+16417.2%) to their portfolio in Q3 2025, for an estimated $701,351
- NEW YORK STATE COMMON RETIREMENT FUND added 10,500 shares (+617.6%) to their portfolio in Q3 2025, for an estimated $208,635
- STRS OHIO removed 2,400 shares (-100.0%) from their portfolio in Q2 2025, for an estimated $34,944
- GPS WEALTH STRATEGIES GROUP, LLC added 450 shares (+45.0%) to their portfolio in Q3 2025, for an estimated $8,941
- CORECAP ADVISORS, LLC removed 388 shares (-44.6%) from their portfolio in Q3 2025, for an estimated $7,709
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$BBNX Analyst Ratings
Wall Street analysts have issued reports on $BBNX in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Stifel issued a "Buy" rating on 10/29/2025
- Piper Sandler issued a "Overweight" rating on 10/29/2025
- Goldman Sachs issued a "Buy" rating on 10/29/2025
- Truist Securities issued a "Buy" rating on 09/22/2025
- Lake Street issued a "Buy" rating on 06/12/2025
- Wolfe Research issued a "Outperform" rating on 05/30/2025
To track analyst ratings and price targets for $BBNX, check out Quiver Quantitative's $BBNX forecast page.
$BBNX Price Targets
Multiple analysts have issued price targets for $BBNX recently. We have seen 7 analysts offer price targets for $BBNX in the last 6 months, with a median target of $31.0.
Here are some recent targets:
- Richard Newitter from Truist Securities set a target price of $32.0 on 10/29/2025
- Matt O'Brien from Piper Sandler set a target price of $32.0 on 10/29/2025
- Jonathan Block from Stifel set a target price of $31.0 on 10/29/2025
- David Roman from Goldman Sachs set a target price of $33.0 on 10/29/2025
- Jeff Johnson from Baird set a target price of $17.0 on 07/30/2025
- Frank Takkinen from Lake Street set a target price of $30.0 on 06/12/2025
- Mike Polark from Wolfe Research set a target price of $20.0 on 05/30/2025
Full Release
IRVINE, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at two upcoming investor conferences (all Eastern Time):
- Wolfe Research 7 th Annual Healthcare Conference on Tuesday, November 18, 2025 at 2:00pm
-
Piper Sandler 37
th
Annual Healthcare Conference on Tuesday, December 2, 2025 at 4:30pm
The presentations will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com , and will be archived there for future replay following the events.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com .
Investor Relations:
Blake Beber
Head of Investor Relations
[email protected]
Media and Public Relations
:
Karen Hynes
Vice President of Marketing
[email protected]
Source: Beta Bionics, Inc.
